Clinical trials
Decompensated Heart Failure clinical trials
Below are recruiting decompensated heart failure clinical trials, each written for real people, not researchers. We’re tracking 152 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07321509RecruitingPhase 4
Digoxin after a recent heart failure hospitalization
This trial tests whether digoxin, a heart medication, can help people who were recently hospitalized for heart failure with a weak heart pump. It aims to see if it improves symptoms and daily activity.
Buenos Aires, Buenos Aires F.D.Ages 18–120 - NCT07269717RecruitingPhase 2
Testing HRS-1893 for heart failure with preserved ejection fraction
This trial tests a new drug called HRS-1893 for people with heart failure with preserved ejection fraction (HFpEF). It aims to see if the drug can improve symptoms and quality of life.
Shanghai, Shanghai MunicipalityAges 40 years+ - NCT06820099RecruitingPhase 2
A drug for heart failure with obesity
This trial tests an oral drug called HRS-7535 for people with a certain type of heart failure (where the heart pumps normally but doesn't relax properly) and who also have obesity. It aims to see if the drug can improve symptoms and daily function.
Beijing, Beijing MunicipalityAges 18–80 - NCT05525663Recruiting
Rehab for older adults after heart failure with strong pumping
This trial studies whether a physical rehabilitation program helps older adults recover and function better after a recent hospital stay for heart failure when the heart’s pumping strength is preserved. It may help you regain walking ability and daily independence after your episode.
Winston-Salem, North CarolinaAges 60 years+ - NCT07592494Recruiting
Arm Exercise Training for Heart Failure With Device
This study compares different types of arm exercises for people with heart failure who have a pacemaker or defibrillator implanted. The goal is to see which exercise approach best improves how well your arms function and help you stay active.
ÇorumAges 18 years+ - NCT07465653RecruitingPhase 1
Study of HJB647 for heart failure with reduced pumping ability
This trial tests a new medicine, HJB647, in people with heart failure who have a weak heart pump. It aims to see if the drug is safe and well-tolerated. You may qualify if your heart's pumping ability is reduced and you are on a specific standard therapy.
Bradenton, FloridaAges 18–100 - NCT07202000RecruitingPhase 2
Exercise and a drug to reduce inflammation for heart failure with preserved ejection fraction
This trial tests whether combining exercise with a medication that blocks a protein called activin can reduce inflammation, improve heart function, and help with thinking in people with heart failure with preserved ejection fraction (HFpEF).
Boston, MassachusettsAges 40 years+ - NCT06244953Recruiting
Heart failure support program with palliative care
This study tests whether a tailored program that includes palliative care (extra support for comfort and quality of life) can help people with advanced heart failure and their family caregivers. It aims to reduce hospital visits and improve well-being.
SingaporeAges 21–99 - NCT05508035RecruitingPhase 3
Testing sacubitril/valsartan vs ramipril for heart failure
This trial compares two blood-pressure and heart-failure medicines: sacubitril/valsartan versus ramipril, to see which improves heart pumping and heart structure over time. It’s aimed at people with ischemic (blocked-artery) heart failure with mid-range ejection fraction and ongoing symptoms.
Krakow, Lesser Poland VoivodeshipAges 18 years+ - NCT06377761Recruiting
Qishen granules for heart failure with preserved pumping function
This trial tests a Chinese herbal medicine called Qishen Granules for people with heart failure who still have a normal pumping ability (ejection fraction 50% or higher). It may help reduce symptoms and improve heart function.
Guangzhou, GuangdongAges 18–85 - NCT06706791RecruitingPhase 4
Empagliflozin for heart failure & diabetes: quality of life study
This trial tests whether a diabetes medicine called empagliflozin can improve the quality of life for people who have both chronic heart failure with a weak heart pump and type 2 diabetes. It compares the effects of adding empagliflozin to your current treatments.
Karachi, SindhAges 40–70 - NCT05583773RecruitingPhase 4
Herbal medicine for heart failure with lower pumping strength
This trial tests SHengXIaN-QuYu decoction (an herbal treatment) in people with symptomatic heart failure and reduced pumping function. It looks to see whether the herbal formula is safe and helpful for heart failure symptoms and heart function.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07318103RecruitingPhase 2
Study of HRS-9057 for fluid retention in heart failure
This trial tests an investigational drug, HRS-9057, in people hospitalized with heart failure who still have fluid buildup despite taking standard diuretics. The goal is to see if HRS-9057 helps remove excess fluid better than current treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06360380Recruiting
Wearable device for fluid removal in heart failure
This trial tests a wearable device that removes extra fluid from your body without using the kidneys. It may help people with heart failure who still have fluid buildup despite taking high doses of water pills.
La Jolla, CaliforniaAges 21–79 - NCT07490067RecruitingPhase 4
Metoprolol for heart failure: genes and drug response
This trial tests how the drug metoprolol works in people with heart failure and reduced pumping function. It looks at whether your genetic makeup affects how the drug is processed and how well it helps your heart.
Ann Arbor, MichiganAges 18 years+ - NCT06678841Recruiting
Pacing therapy for heart failure with preserved pumping ability
This study tests a new pacing approach for people with a specific type of heart failure (HFpEF) to see if it can improve symptoms and quality of life. It involves a pacemaker-like device that adjusts heart rate based on your needs.
Phoenix, ArizonaAges 40 years+ - NCT07375433Recruiting
Heart failure and COPD study for patients aged 50 to 70
This trial looks at how heart failure with preserved pumping function affects people who also have COPD. It aims to understand the course of the disease and long-term outlook.
Kazan'Ages 50–70 - NCT07851779RecruitingPhase 4
Stopping heart failure drugs after excellent response to cardiac resynchronization therapy
This trial studies whether patients with non-ischemic cardiomyopathy who have responded extremely well to a special pacemaker (CRT) can safely stop their heart failure medications. It aims to see if their heart function stays stable without these drugs.
L'Hospitalet de Llobregat, BarcelonaAges 18 years+ - NCT05834803Recruiting
Stenting narrowed kidney artery to help high-risk patients
This trial studies whether placing a small stent in a severely narrowed kidney artery can improve outcomes for people with high-risk, artery-hardening kidney blood-flow problems. It focuses on people whose high blood pressure or kidney function has been getting worse despite multiple medications.
Aarhus NAges 18 years+ - NCT05958706Recruiting
Testing how heart cells use fuel in heart failure
This study looks at how the heart uses energy fuel in people with heart failure, including those with type 2 diabetes. It may help researchers understand what’s going on inside the heart and how it could be treated in the future.
DüsseldorfAges 20–85 - NCT07345533Recruiting
Heart Failure Monitoring with a Chest Sensor
This study tests a small chest sensor that tracks your heart activity while you're in the hospital. It may help doctors better manage heart failure and prevent future crises.
CaenAges 18–90 - NCT06942221Recruiting
Digital Heart Failure Support After Hospital Stay
This trial tests a digital health tool to help manage heart failure medications after you leave the hospital. If you were recently hospitalized for heart failure and have a smartphone or tablet, you may be able to join.
BaselAges 18 years+ - NCT06762964RecruitingPhase 2
Dapagliflozin for Failing Fontan Circulation
This study tests whether a medication called dapagliflozin (a pill for heart failure) can help people with a Fontan circulation who feel short of breath. It aims to improve symptoms and quality of life.
Rochester, MinnesotaAges 18 years+ - NCT06217302RecruitingPhase 3
Sotagliflozin for kidney protection in type 1 diabetes
This study tests whether sotagliflozin (a pill that helps control blood sugar and protects the kidneys) can slow down kidney function decline in people with type 1 diabetes and diabetic kidney disease. You may qualify if you have had type 1 diabetes for at least 8 years, have moderate kidney damage, and are on standard treatments.
Stanford, CaliforniaAges 18–75
Hear when a new Decompensated Heart Failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for decompensated heart failure?
- Yes. Clin2 currently lists 152 recruiting decompensated heart failure studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a decompensated heart failure trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a decompensated heart failure trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.